Gsk Share Discussion Threads

[spud] 28/7/2021 14:27

I still fail to understand why it takes 2 years plus to split a company.....

spud

[alphorn] 28/7/2021 14:25

Not a particularly bullish commentary - detail of destocking etc..... IMO poorly written.

Contrast that with this statement from Pfizer today - ...."we remain highly confident in our ability to achieve at least a 6% compound annual growth rate through 2025 and intend to build upon our recent successes by continuing to follow the science, trust in our people and remain focused on delivering breakthroughs for the patients we serve.”

It will be interesting to read what AZN have to say tomorrow.

Remember these are both global companies with audiences around the world.

[montyhedge] 28/7/2021 14:24

McFlies
Simple answer, no growth, shareprice below what it was 25 years ago, dividend to be cut 30% in 2022 and in 2023. I thought the holy grail of investing shareprice growth plus growing dividends, this is the opposite of the holy grail.

[mcflies] 28/7/2021 14:20

Here's a profound question seeking an answer.
WHY DOES EVERYONE HATE THIS COMPANY?

[waldo2020] 28/7/2021 14:18

It'll be interesting to know what products will be part of the demerged group. Considering how depressed the share price have been for the last two years, I hope the sum of the parts are greater than the whole

[alex1621] 28/7/2021 14:15

Difficult to say. If these results are replicated in the next few quarters then Elliot would have little leverage over what happens to GSK, that might be a factor. Sometimes good news is sold into. I focus on the numbers, and on the whole I'm happy with them.

[eurofox] 28/7/2021 14:12

added at 1384.2

[mcflies] 28/7/2021 14:11

net
The BoD's should be asking themselves that question right now

[spud] 28/7/2021 14:10

GlaxoSmithKline 2Q Net Profit Fell Despite Higher Sales; Backs 2021 Outlook -- UpdateSource: Dow Jones NewsBy Cecilia Butini GlaxoSmithKline PLC said Wednesday that second-quarter net profit fell from the previous year, though sales grew, and backed its outlook for the full year.The British pharmaceutical major posted net profit of 1.40 billion pounds ($1.94 billion) for the period, down from GBP2.26 billion the year prior. Adjusted earnings per share were 28.1 pence compared with 19.2 pence for the same period a year earlier.Sales came in at GBP8.09 billion, up from GBP7.62 billion for the second quarter of 2020, when both pharmaceuticals and vaccine sales were affected by the coronavirus pandemic.Pharmaceuticals sales rose 3%, driven by growth in new products and specialty products and as a result of favorable comparables with the previous year, which was hit by destocking following pent-up demand in the first quarter, the company said.Vaccine turnover grew 39% on year, GlaxoSmithKline said. However, the company said that its performance continued to be hurt by lower demand for routine adult vaccination due to Covid-19 vaccination programs taking priority. GlaxoSmithKline said it expects vaccine revenue for 2021 to be broadly flat.The company backed a previously given outlook for 2021, saying that it expects adjusted EPS to decline by mid-to-high single-digit percentage at constant exchange rates. Regarding 2022, it said it expects meaningful improvements in revenues and margins.GlaxoSmithKline declared a dividend of 19 pence a share for the second quarter and said it continues to expect a dividend of 80 pence a share for the full year 2021.The company said it expects sales of its solutions for Covid-19, including vaccine adjuvants and monoclonal-antibody treatment sotrovimab, to contribute approximately between 4% and 6% to full-year adjusted EPS growth.spud

[netcurtains] 28/7/2021 14:05

Scratch head
What’s going on?

[netcurtains] 28/7/2021 14:04

Blimy who would have thought good results would make price fall

[alex1621] 28/7/2021 13:51

And that's why Astra's vaccine received such poor PR. Dirty tricks department at work.

[mcflies] 28/7/2021 13:38

'how come Pfizer can charge for the vaccine but others like Astra cannot?'

The answer is that Astra could have charged a profit but chose not to. They didn't want to take advantage of a desperate situation. Pfizer saw it as an opportunity to make some big bucks. It's about high moral values versus greed.

[netcurtains] 28/7/2021 13:36

Based on these figures what is the current PE ratio of GSk?

[netcurtains] 28/7/2021 13:27

Looking good for steady climb over next few weeks

[mcflies] 28/7/2021 13:26

This massive drop from today's highs would suggest Elliott is now out? The figures are not bad enough for them to force any changes.

[abdullla] 28/7/2021 13:20

How come Pfizer can charge for the vaccine but others like Astra cannot?

[spoole5] 28/7/2021 13:19

Down again. Emma speak?!

[alex1621] 28/7/2021 13:19

Where is Sanofi selling its vaccine? It has not been approved anywhere. So this might be payment for what has been used in the trials.

[alphorn] 28/7/2021 13:12

Pfizer posted some big numbers today and lifted its 2021 projection for Covid-19 vaccine revenues to $33.5bn up from the May forecast of $26bn.

Pfizer said the pre-tax profit margin on the Covid-19 vaccine was in the "high-20s" in terms of percent. (France24).

No wonder Pfizer has outpaced GSK in recent years.

[abdullla] 28/7/2021 13:12

Sanofi & GSK together are partners in the sale of covid vaccine which includes supplying them with the Adjuvant .

[alphorn] 28/7/2021 13:02

Market reaction probably not surprising. The company has signalled to the world that the group is not a sustainable model as it stands - not a particulary glowing assessment.
(Continue to hold on the basis of the breakup where I expect predators).

[alphorn] 28/7/2021 12:57

H1 included £258m for the sale of its adjuvant. Looks as though Sanofi will get the lion's share of any new vaccine.

[alex1621] 28/7/2021 12:56

The net profit of £1.4bn is much higher than the consensus forecast of £0.6bn ... GSK delivered ahead of expectations in all areas.